Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;103:2550-2554

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gibson, C. M.
Right arrow Articles by Braunwald, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gibson, C. M.
Right arrow Articles by Braunwald, E.
Related Collections
Right arrow Thrombin
Right arrow Platelet function inhibitors
Right arrow Acute myocardial infarction

(Circulation. 2001;103:2550.)
© 2001 American Heart Association, Inc.


Clinical Investigation and Reports

Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction

A TIMI 14 Substudy

C. Michael Gibson, MS, MD; James A. de Lemos, MD; Sabina A. Murphy, MPH; Susan J. Marble, RN, MS; Carolyn H. McCabe, BS; Christopher P. Cannon, MD; Elliott M. Antman, MD; Eugene Braunwald, MD; for the TIMI Study Group

From Harvard Clinical Research Institute, Boston, Mass (C.M.G., S.A.M., S.J.M.); the University of Texas Southwestern Medical Center, Dallas, Tex (J.A.d.L.); and the Department of Medicine, Brigham and Women’s Hospital, Boston, Mass (C.H.M., C.P.C., E.M.A., E.B.).

Background—Use of abciximab in combination with administration of thrombolytics has been shown to improve epicardial and microvascular coronary blood flow in acute myocardial infarction (AMI). As a potential mechanism, we hypothesized that combination therapy would reduce angiographically evident thrombus (AET) and would increase lumen diameter compared with thrombolytic monotherapy.

Methods and Results—Patients who received combination therapy in TIMI 14 (low-dose thrombolytic plus abciximab, n=732) were compared with patients who received thrombolytic monotherapy without abciximab in the TIMI 4, 10A, 10B, and 14 trials (n=1662). Thrombus burden was assessed 90 minutes after treatment, and quantitative angiography was performed in an angiographic core laboratory by investigators blinded to treatment assignment. The frequency of AET was reduced in patients who received abciximab combination therapy compared with thrombolytic monotherapy (26.6% versus 35.4%, P<0.001). Similar findings were observed when the analysis was restricted to patients with patent arteries (14.7% versus 20.8%, P=0.001). Residual percent diameter stenosis at 90 minutes was also improved in the abciximab therapy group both in patent arteries (64.6±16.6 versus 68.3±14.8, P<0.001) and between patent and occluded arteries (69.3±19.5 versus 73.8±17.9, P<0.001). The absence of AET was associated with an increased frequency of >70% ST-segment resolution by 90 minutes (37.2%, 110/296 versus 18.9%, 54/286, P<0.001).

Conclusions—Compared with thrombolytic monotherapy, combination therapy with abciximab reduces AET, which in turn is associated with reduced residual stenosis and improved ST-segment resolution in AMI. These data provide a pathophysiological link between platelet inhibition, reduced thrombus, and improvements in both epicardial and microvascular perfusion in AMI.


Key Words: thrombus • abciximab • blood flow • myocardial infarction • thrombolysis




This article has been cited by other articles:


Home page
Eur Heart JHome page
M. Napodano, A. Ramondo, G. Tarantini, D. Peluso, S. Compagno, C. Fraccaro, A. C. Frigo, R. Razzolini, and S. Iliceto
Predictors and time-related impact of distal embolization during primary angioplasty
Eur. Heart J., February 1, 2009; 30(3): 305 - 313.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
F. Burzotta, A. Parma, C. Pristipino, A. Manzoli, F. Belloni, G. Sardella, S. Rigattieri, A. Danesi, P. Mazzarotto, F. Summaria, et al.
Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study
Eur. Heart J., December 2, 2008; 29(24): 3011 - 3021.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
G. Niccoli, S. Giubilato, E. Russo, C. Spaziani, A. Leo, I. Porto, A. M. Leone, F. Burzotta, S. Riondino, F. Pulcinelli, et al.
Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention
Eur. Heart J., August 1, 2008; 29(15): 1843 - 1850.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Chechi, S. Vecchio, G. Vittori, G. Giuliani, A. Lilli, G. Spaziani, L. Consoli, G. Baldereschi, G. G.L. Biondi-Zoccai, I. Sheiban, et al.
ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients.
J. Am. Coll. Cardiol., June 24, 2008; 51(25): 2396 - 2402.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. Isaaz
Role of percutaneous coronary minimalist intervention in the management of acute ST-segment elevation myocardial infarction.
J. Am. Coll. Cardiol., March 11, 2008; 51(10): 1046 - 1047.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. Sianos, M. I. Papafaklis, J. Daemen, S. Vaina, C. A. van Mieghem, R. T. van Domburg, L. K. Michalis, and P. W. Serruys
Angiographic Stent Thrombosis After Routine Use of Drug-Eluting Stents in ST-Segment Elevation Myocardial Infarction: The Importance of Thrombus Burden
J. Am. Coll. Cardiol., August 14, 2007; 50(7): 573 - 583.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. J. Kirtane, J. J. Vafai, S. A. Murphy, J. M. Aroesty, M. S. Sabatine, C. P. Cannon, C. M. Gibson, and for the TIMI Study Group
Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy
Eur. Heart J., September 1, 2006; 27(17): 2040 - 2045.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
G. Niccoli, G. A. Lanza, S. Shaw, E. Romagnoli, D. Gioia, F. Burzotta, C. Trani, M. A. Mazzari, R. Mongiardo, M. De Vita, et al.
Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization
Eur. Heart J., August 1, 2006; 27(15): 1793 - 1798.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Lefevre, E. Garcia, B. Reimers, I. Lang, C. di Mario, A. Colombo, F.-J. Neumann, M. V. Chavarri, P. Brunel, E. Grube, et al.
X-Sizer for Thrombectomy in Acute Myocardial Infarction Improves ST-Segment Resolution: Results of the X-Sizer in AMI for Negligible Embolization and Optimal ST Resolution (X AMINE ST) Trial
J. Am. Coll. Cardiol., July 19, 2005; 46(2): 246 - 252.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. M. Gibson, J. Karha, S. A. Murphy, J. A. de Lemos, D. A. Morrow, R. P. Giugliano, M. T. Roe, R. A. Harrington, C. P. Cannon, E. M. Antman, et al.
Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction
J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1170 - 1176.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. T. Roe, C. L. Green, R. P. Giugliano, C. M. Gibson, K. Baran, M. Greenberg, S. T. Palmeri, S. Crater, K. Trollinger, K. Hannan, et al.
Improved speed and stability of st-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute st-segment elevation myocardial infarction
J. Am. Coll. Cardiol., February 18, 2004; 43(4): 549 - 556.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Napodano, G. Pasquetto, S. Sacca, C. Cernetti, V. Scarabeo, P. Pascotto, and B. Reimers
Intracoronary thrombectomy improves myocardial reperfusion in patients undergoing direct angioplasty for acute myocardial infarction
J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1395 - 1402.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
H.-K. Yip, C.-J. Wu, H.-W. Chang, Y.-K. Hsieh, C.-Y. Fang, S.-M. Chen, and M.-C. Chen
Impact of Tirofiban on Angiographic Morphologic Features of High-Burden Thrombus Formation During Direct Percutaneous Coronary Intervention and Short-term Outcomes
Chest, September 1, 2003; 124(3): 962 - 968.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
F Burzotta, M Hamon, R Sabatier, F Prati, A Boccanelli, and G Grollier
Large intracoronary thrombi with good TIMI flow during acute myocardial infarction: four cases of successful aggressive medical management in patients without angiographically detectable coronary atherosclerosis
Heart, December 1, 2002; 88(5): e6 - 6.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
H.-K. Yip, M.-C. Chen, H.-W. Chang, C.-L. Hang, Y.-K. Hsieh, C.-Y. Fang, and C.-J. Wu
Angiographic Morphologic Features of Infarct-Related Arteries and Timely Reperfusion in Acute Myocardial Infarction: Predictors of Slow-Flow and No-Reflow Phenomenon
Chest, October 1, 2002; 122(4): 1322 - 1332.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. P. Cannon
Importance of TIMI 3 Flow
Circulation, August 7, 2001; 104(6): 624 - 626.
[Full Text] [PDF]